Your browser doesn't support javascript.
loading
Antibiotic Use during the COVID-19 Pandemic in a Tertiary Hospital with an Ongoing Antibiotic Stewardship Program.
Henig, Oryan; Kehat, Orli; Meijer, Suzy E; Chikly, Amanda; Weiss-Meilik, Ahuva; Egoz, Eyal; Ben-Ami, Ronen; Paran, Yael.
Afiliación
  • Henig O; Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
  • Kehat O; Medata AI Center, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Meijer SE; Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
  • Chikly A; Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
  • Weiss-Meilik A; Medata AI Center, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Egoz E; Medata AI Center, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Ben-Ami R; Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
  • Paran Y; Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
Antibiotics (Basel) ; 10(9)2021 Aug 31.
Article en En | MEDLINE | ID: mdl-34572638
During the recent pandemic, the fact that the clinical manifestation of COVID-19 may be indistinguishable from bacterial infection, as well as concerns of bacterial co-infection, have been associated with an increased use of antibiotics. The objective of this study was to assess the effect of targeted antibiotic stewardship programs (ASP) on the use of antibiotics in designated COVID-19 departments and to compare it to the antibiotic use in the equivalent departments in the same periods of 2018 and 2019. Antibiotic consumption was assessed as days of treatment (DOT) per 1000 patient days (PDs). The COVID-19 pandemic was divided into three periods (waves) according to the pandemic dynamics. The proportion of patients who received at least one antibiotic was significantly lower in COVID-19 departments compared to equivalent departments in 2018 and 2019 (Wave 2: 30.2% vs. 45.6% and 44.9%, respectively; Wave 3: 30.5% vs. 47.8% and 50.1%, respectively, p < 0.001). The DOT/1000PDs in every COVID-19 wave was lower than during similar periods in 2018 and 2019 (179-282 DOT/1000PDs vs. 452-470 DOT/1000PDs vs. 426-479 DOT/1000PDs, respectively). Moreover, antibiotic consumption decreased over time during the pandemic. In conclusion, a strong ASP is effective in restricting antibiotic consumption, particularly for COVID-19 which is a viral disease that may mimic bacterial sepsis but has a low rate of concurrent bacterial infection.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antibiotics (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Suiza